Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D James

Showing results (161-170 of 198) with videos related to

Pageof 20
Sort By:
The Lancet. Oncology|July 6, 2023
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trialsClaire L Vale, David J Fisher, Peter J Godolphin, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
Nature|November 9, 2022
The neurons that restore walking after paralysisClaudia Kathe, Michael A Skinnider, Thomas H Hutson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2025
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath TrialRichard T Bryan, Wenyu Liu, Sarah J Pirrie, et al.
European Urology|July 15, 2017
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer TrialChristopher C Parker, Robert E Coleman, Oliver Sartor, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
The Lancet. Oncology|April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
Contemporary Clinical Trials|March 27, 2024
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trialsMatthew R Sydes, Macey L Murray, Saiam Ahmed, et al.
Pageof 20

Showing results (161-170 of 198) with videos related to

Sort By:
Pageof 20
The Lancet. Oncology|July 6, 2023
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trialsClaire L Vale, David J Fisher, Peter J Godolphin, et al.
International Journal of Radiation Oncology, Biology, Physics|March 20, 2019
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder CancerAlexandra K Walker, Katalin Karaszi, Helen Valentine, et al.
European Urology|December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsGuru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
Nature|November 9, 2022
The neurons that restore walking after paralysisClaudia Kathe, Michael A Skinnider, Thomas H Hutson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2025
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath TrialRichard T Bryan, Wenyu Liu, Sarah J Pirrie, et al.
European Urology|July 15, 2017
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer TrialChristopher C Parker, Robert E Coleman, Oliver Sartor, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
The Lancet. Oncology|April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
Contemporary Clinical Trials|March 27, 2024
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trialsMatthew R Sydes, Macey L Murray, Saiam Ahmed, et al.
Pageof 20